Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) / F. Salton, P. Confalonieri, S. Centanni, M. Mondoni, N. Petrosillo, P. Bonfanti, G. Lapadula, D. Lacedonia, A. Voza, N. Carpenè, M. Montico, N. Reccardini, G.U. Meduri, B. Ruaro, M. Confalonieri. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 1399-3003. - 61:4(2023 Apr), pp. 2201514.1-2201514.10. [10.1183/13993003.01514-2022]
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
S. Centanni;M. Mondoni;P. Bonfanti;G. Lapadula;M. Confalonieri
2023
Abstract
Dysregulated systemic inflammation is the primary driver of mortality in severe COVID-19 pneumonia. Current guidelines favor a 7-10-day course of any glucocorticoid equivalent to dexamethasone 6 mg·day-1. A comparative RCT with a higher dose and a longer duration of intervention was lacking.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Eur Respir J-2023-Salton-2201514.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
937.11 kB
Formato
Adobe PDF
|
937.11 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
